Tolero Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Scott Albert Pearce

Koc-Kan Ho

Yong Xu

Jihua Liu

Xiaohui Liu

Kenneth Mark Parnell

Michael David Saunders

Jason Marc Foulks

Kevin Bret Wright

Steven Brian Kanner

David Lee Vollmer

Micheal David Saunders

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, Rand Rare as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

PKM2 modulators and methods for their use

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Growing community of inventors

Clearfield, UT, United States of America

Scott Albert Pearce